Brii Biosciences Report Interim Results from P-II Study of BRII-179 (VBI-2601) + PEG-IFNα for the Treatment of Chronic Hepatitis B
Shots:
- The cohort-level unblinded 24 & 36wk. results from an interim analysis of the P-II study of BRII-179 (Pre-S1/Pre-S2/S therapeutic vaccine) + pegylated interferon-alpha (PEG-IFNα) vs PEG-IFNα in patients with CHB
- In the intent-to-treat analysis & per protocol analysis, the cohort level unblinded data showed that 26.3% with BRII-179/PEG-IFNα achieved HBsAg loss vs 19.3% with PBO/PEG-IFNα & 32.6% vs 21.6% at 24wk.; 24.6% vs 14.0% & 31.8% vs 14.9% at 36wk., respectively. The therapy was safe and tolerated with AEs similar to those associated with PEG-IFNα or BRII-179 as previously reported
- As per protocol analysis, 9 out of 15 patients achieved HBsAg seroconversion at 24wk. vs 1 out of 11 with PEG-IFNα alone. BRII-179 is being studied in 2 P-II trials in combination with BRII-835 (VIR-2218) & PEG-IFNα for chronic HBV inf.
Ref: PRNewswire | Image: Brii Biosciences
Related News:- Brii Biosciences Launches Amubarvimab/Romlusevimab Combination in China for the Treatment of COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
